Filament Health

What Filament Health does

Filament Health is a clinical-stage natural psychedelic drug development company founded in 2020 and headquartered in Vancouver, Canada. Its core focus is the development of botanical psilocybin drug candidates, with PEX010 serving as the lead candidate — a naturally-sourced psilocybin capsule being investigated for mental health indications. The company holds 76 issued patents across 15 patent families covering extraction, formulation, and therapeutic applications, and supplies PEX010 to more than 80 clinical research sites globally under Health Canada and FDA regulatory frameworks.

Filament operates a drug-development rather than consumer-facing business model. Revenue is generated primarily through licensing agreements (e.g., Reset Pharma, NeoLumina Bioscience), fee-for-service clinical drug supply to academic and research institutions, and the Magdalena Biosciences joint venture. A meaningful portion of product is provided at low or no cost to academic researchers to support clinical trials and data generation. The company held Health Canada psilocybin dealer licenses, GMP-compliant manufacturing capabilities, and multiple FDA INDs as of disclosure.

Filament was acquired by Red Light Holland Corp. with the transaction effective April 29, 2026. At the time of acquisition, Filament employed between 11 and 50 people, reported only $268,522 in Q3 2025 revenue, and held $337,082 in cash as of September 30, 2025 — figures consistent with a pre-commercial clinical-stage operation rather than a revenue-generating pharmaceutical company.

Name

Filament Health

Legal name

Filament Health Corp.

Website

https://filament.health

Company type

Public

Founded year

2020

Operating status

Acquired

Headcount range

11–50 employees

Short description

Filament Health is a clinical-stage Vancouver-based developer of botanical psilocybin drug candidates, primarily PEX010, supplied to 80+ research sites and licensed to partners for mental health clinical trials.

Ownership category

akta.pro rank

Headquarters

HQ city

Vancouver

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Infrastructure

Revenue model

1. Licensing Agreements: Revenue generated from licensing PEX010 and associated intellectual property to pharmaceutical companies for use in their clinical trials. Partners include Reset Pharma, NeoLumina Bioscience, and other biotechnology companies.
2. Clinical Drug Supply: Supply of pharmaceutical-grade botanical psychedelic drug candidates to academic institutions and research organizations conducting clinical trials. The company provides drugs at low or no cost for qualified academic and philanthropic research.
3. Compassionate Use Program Supply: Supply of PEX010 to patients under compassionate use programs in Germany and other authorized jurisdictions, typically provided free of charge for treatment-resistant conditions.
4. Strategic Partnership Revenue: Following acquisition by Red Light Holland in April 2026, Filament operates as a wholly owned subsidiary contributing to combined entity revenue through its manufacturing capabilities, patents, and clinical programs.

Go-to-market motion2 records

Distribution channels6 records

Marketing channels5 records

Core offering

Filament Health is a clinical-stage pharmaceutical company that develops, manufactures, and supplies standardized botanical psychedelic drug candidates—primarily PEX010, a patented 25mg botanical psilocybin drug candidate—to clinical research institutions, academic universities, and licensing partners worldwide. The company also operates GMP-compliant manufacturing and provides drug access through compassionate use programs, supplying over 80 active clinical research sites globally for mental health and substance use disorder indications.

Product overview

Filament Health is a clinical-stage natural psychedelic drug development company offering a portfolio of botanical psychedelic drug candidates and pharmaceutical manufacturing services. The core product is PEX010, a patented 25mg botanical psilocybin drug candidate supplied to over 80 clinical research sites globally. Additional products include a psilocin drug candidate, iboga extract, and coca leaf extract (via Magdalena Biosciences joint venture). The company provides GMP drug manufacturing, compassionate use access programs, and clinical trial licensing services through partnerships with academic institutions worldwide.

Differentiator

Problem solved

Functional benefit

Products and services

• PEX010 Botanical Psilocybin Drug Candidate Patented standardized botanical psilocybin drug candidate (25mg) derived from natural psilocybin mushrooms, currently supplied to over 80 clinical research sites globally for mental health indications including treatment-resistant depression, PTSD, alcohol use disorder, opioid use disorder, methamphetamine use disorder, and Alzheimer's research.
• PEX010 Microdose Format First GMP-compliant standardized microdose format of PEX010, introduced through an expanded New Zealand partnership with Allu Therapeutics to support New Zealand's regulatory framework permitting authorized psychiatrists to prescribe psilocybin to treatment-resistant patients.
• Psilocin Drug Candidate Botanical psilocin drug candidate derived from natural magic mushrooms using Filament's proprietary de-phosphorylation process. Currently being studied in clinical trials at UCSF comparing effects of psilocybin and psilocin botanical drugs.
• Iboga Total Alkaloid Extract Total alkaloid iboga extract developed from Nagoya Protocol-compliant iboga root imported from Gabon in partnership with Terragnosis. Iboga contains ibogaine and shows promise for treating substance use disorders.
• Coca Leaf Extract (Magdalena Biosciences) Coca leaf extract being developed by Magdalena Biosciences joint venture (Filament Health and Jaguar Health) for mental health indications including ADHD and post-GLP-1 weight management, under FDA botanical drug guidance.
• GMP Drug Manufacturing Services In-house pharmaceutical manufacturing services through GMP-compliant Vancouver facility for producing standardized psychedelic drug candidates. Includes regulatory and logistics expertise supporting global clinical trial supply across multiple jurisdictions.
• Compassionate Use / Drug Access Program Program enabling healthcare professionals and authorized prescribers to request access to non-marketed psychedelic drugs for patients with serious or life-threatening conditions, including Germany's first EU compassionate use program for psilocybin and Health Canada's Special Access Program.
• Clinical Trial Licensing & Supply Licensing partnerships and drug supply to academic and research institutions conducting clinical trials worldwide. Provides low or no-cost study drugs for qualified research with over 80 active clinical sites, including licensing partners Reset Pharma and NeoLumina Bioscience.

Quantifiable outcome

• 69% of participants fell below clinical thresholds for anxiety and depression after second psilocybin treatment with improvements sustained for up to 24 weeks
• +2 more outcomes

Named customers12 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

15 partnerships are on record, tiered flagship and core.

• GHU Paris Psychiatrie & NeurosciencesflagshipStrategic or Co-development Partner · 8 June 2026Agreement for Filament to supply PEX010 botanical psilocybin drug candidate for the KETAPSYCHECOG academic clinical study in France. This randomized, double-blinded, cross-over trial compares behavioral and neural effects of psilocybin and ketamine in healthy volunteers. The agreement adds France to Filament's expanding international clinical research footprint.
• UCSF (University of California, San Francisco)flagshipStrategic or Co-development Partner · 4 June 2026UCSF selected PEX010 for a double-blind, randomized clinical trial investigating psychedelics in healthy older adults with low well-being and biomarkers for preclinical Alzheimer's disease. The study examines neuroinflammation markers via EEG and MRI. Filament's PEX010 is now selected for more than 80 academic and research studies worldwide.
• Allu TherapeuticscoreChannel Partner/ Reseller/ Distributor · 25 May 2026Expanded New Zealand partnership with Allu Therapeutics adding Filament Health as a supplying affiliate under existing supply agreement. Introduces first GMP-compliant standardized microdose format of PEX010, differentiating from synthetic formulations. Supports New Zealand's regulatory framework permitting authorized psychiatrists to prescribe psilocybin to treatment-resistant patients.
• Red Light HollandcoreStrategic or Co-development Partner · 29 April 2026Red Light Holland completed acquisition of Filament Health effective April 29, 2026, through a statutory plan of arrangement under British Columbia law. Former Filament shareholders received Red Light shares at an exchange ratio of 0.36634769 per share, holding approximately 30% of the combined entity. The transaction creates a vertically integrated psychedelic drug development platform combining Red Light's global distribution footprint with Filament's pharmaceutical-grade capabilities.
• University College LondonflagshipStrategic or Co-development Partner · 24 July 2025Partnership to supply PEX010 for two Phase 2 clinical trials exploring effects on brain function, perception, and psychological wellbeing.
• University of British ColumbiaflagshipStrategic or Co-development Partner · 10 October 2023Health Canada-approved Phase 2 clinical trial at UBC studying PEX010 for opioid use disorder. Led by Dr. Christian Schütz, Professor of Psychiatry.
• ENACO (Empresa Nacional de la Coca)coreOthers · 21 September 2023Peruvian state company authorized to collect, distribute, and export coca leaf. Coca leaf import completed for Magdalena Biosciences research into ADHD and neuropsychiatric indications, conducted under authorization of Peruvian Health Authority DIGEMID.
• Reset PharmacoreOEM/ Whitelabel/ Licensing Partner · 31 August 2023Licensing agreement granting Reset Pharma use of PEX010 for Phase 2 FDA clinical trial for demoralization syndrome in cancer patients. PEX010 is formulated as a capsule for oral administration. Reset Pharma joins growing list of Filament licensing partners.
• UCSFflagshipStrategic or Co-development Partner · 7 July 2023FDA-authorized Phase 2 clinical trial at UCSF studying PEX010 for methamphetamine use disorder. This was the first FDA study to administer natural psychedelic drug candidates.
• NeoLumina BiosciencecoreOEM/ Whitelabel/ Licensing Partner · 30 June 2023Exclusive licensing agreement with NeoLumina Bioscience for use of PEX010 in proprietary clinical development programs.
• TerragnosiscoreStrategic or Co-development Partner · 17 May 2023Partnership for ibogaine extract production from Nagoya Protocol-compliant iboga root imported from Gabon. Terragnosis is dedicated to producing ethically sourced, high-quality ibogaine and iboga extracts. Extract will be delivered to Ambio Life Sciences for retreat facilities in Mexico.
• University of WashingtonflagshipStrategic or Co-development Partner · 15 March 2023FDA-approved Phase 2 clinical trial at University of Washington studying PEX010 for PTSD and alcohol use disorder in military veterans and first responders. Also conducted Phase 1 study for anxiety in metastatic cancer patients.
• Centre for Addiction and Mental Health (CAMH)flagshipStrategic or Co-development Partner · 14 February 2023Multiple psilocybin supply agreements with CAMH for Phase 2 trials in treatment-resistant depression and dementia/mild cognitive impairment.
• Psychiatric Centre CopenhagenflagshipStrategic or Co-development Partner · 18 January 2023Clinical trial approval for Phase 2 study of PEX010 for alcohol use disorder at Copenhagen University Hospital.
• Jaguar HealthcoreStrategic or Co-development Partner · 10 January 2023Joint venture formed in January 2023 to create Magdalena Biosciences for developing novel natural prescription medicines for mental health indications. Filament contributes botanical drug development expertise; Jaguar provides plant library of 2,300 medicinal plants and 3,500 plant extracts. One Small Planet committed US$1,000,000 in funding. Focus areas include ADHD, weight management, and neuropsychiatric indications using coca leaf extract.

Scale indicators8 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• Compass Pathways: Compass Pathways develops synthetic COMP360 psilocybin therapy for treatment-resistant depression and is the most advanced psychedelic drug developer. It is Filament's closest direct competitor because both target the same patient populations with psilocybin, but Compass uses a synthetic single-molecule API versus Filament's botanical multi-compound approach, making regulatory and commercial head-to-head comparison inevitable.
• MindMed: MindMed is a clinical-stage psychedelic medicine company developing MM-120 (lysergic acid diethylamide D-tartrate) for generalized anxiety disorder and other CNS indications. It is a direct peer because both companies pursue FDA-regulated psychedelic drug development with similar B2B clinical-trial-supply GTM motions and similar capital markets profiles.
• GH Research: GH Research is developing GH001, a proprietary mebufotenin (5-MeO-DMT) formulation, for treatment-resistant depression with Phase 2b data. Comparable to Filament because both are clinical-stage companies focused on psychedelic APIs for the same TRD indication and rely on specialized manufacturing plus clinical supply partnerships.
• Cybin Inc: Cybin is a clinical-stage psychedelic company developing CYB003 (deuterated psilocin) for major depressive disorder. It is comparable to Filament because both target MDD/TRD with psychedelic-derived molecules, both have global clinical supply ambitions, and both face similar regulatory and capital markets dynamics.
• Beckley Psytech: Beckley Psytech develops intranasal psychedelic formulations (psilocybin, DMT) for neuropsychiatric indications including cluster headache and depression. Comparable to Filament because both are clinical-stage psychedelic drug developers pursuing FDA-regulated pathways and both rely on specialized drug delivery innovation rather than generic oral dosing.

Broad incumbents

• Atai Life Sciences: Atai Life Sciences is a clinical-stage biopharmaceutical company with a broad portfolio of psychedelic and non-psychedelic mental health assets. Comparable to Filament as a broad incumbent because it pursues the same psychedelic therapy thesis (multiple compounds, multiple indications) with greater capital and a wider pipeline, positioning it as a platform competitor.

Emerging players

• Jaguar Health: Jaguar Health is a commercial-stage botanical pharmaceutical company and Filament's joint venture partner in Magdalena Biosciences. It is an emerging player peer because both companies pursue FDA botanical drug pathways, share proprietary plant extract IP (Jaguar's crofelemer and plant library), and co-develop botanical APIs for mental health and gastrointestinal indications.
• Field Trip Health: Field Trip Health operates psychedelic-assisted therapy clinics and develops novel psychedelic compounds including FT-104. It is an emerging player peer because it represents the clinical delivery side of the same psychedelic therapy value chain Filament supplies into, and competes for the same patient populations in depression and PTSD.
• CaaMTech: CaaMTech is a research-focused psychedelic drug discovery company developing novel synthetic and semi-synthetic tryptamines. It is an emerging player peer because it operates in the same psychedelic drug discovery space, supplies clinical research sites with novel compounds, and competes for similar investor and partner mindshare, though focused more upstream on discovery than Filament's clinical-supply business.

Others

• Red Light Holland: Red Light Holland is Filament's parent company following the April 2026 acquisition. It is an "others" peer because it is the integrated acquirer rather than a direct competitor — combining Filament's pharmaceutical-grade drug development with Red Light's global distribution network for legal psychedelics, including truffles in the Netherlands.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/FilamentHealth
• YouTubeyoutube.com/channel/UCAxfMFeIN59605vLXHch5sw
• LinkedInca.linkedin.com/company/filament-health
• Instagraminstagram.com/filamenthealth

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries2 records

Funding overview

Funding rounds7 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Filament Health